SCHEMBL2767964

SCHEMBL2767964

O=Cc1ccc2nnsc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
CLK1 P49759 5/20 0.42
DYRK1A Q13627 5/20 0.42
CLK4 Q9HAZ1 5/20 0.42
DYRK1B Q9Y463 5/20 0.42
CLK2 P49760 3/20 0.42
DYRK3 O43781 2/20 0.42
CLK3 P49761 1/20 0.42
DYRK2 Q92630 1/20 0.41
BAZ1A Q9NRL2 3/20 0.41
KDM4E B2RXH2 2/20 0.41
PTGS2 P35354 1/20 0.41
CYP2A6 P11509 1/20 0.39
NSD2 O96028 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
PRMT3 O60678 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2767305 0.85 THRB (0.46) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL21376072 0.73 NPC1 (0.54) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL16782399 0.71 ALDH1A1 (0.44) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL7576448 0.69 MAPT (0.46) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL1291431 0.69 NPC1 (0.42) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL1292012 0.69 SMN1; SMN2 (0.46) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL2211494 0.69 ALDH1A1 (0.46) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL17538782 0.69 PRMT3 (0.48) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL10630197 0.69 BAZ1A (0.47) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL1418925 0.69 DYRK1A (0.52) ALDH1A1RAB9ANPC1CLK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 US disclosed
EP-4422753-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2024-09-04 EP disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 WO disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 WO disclosed
US-20100184751-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS BALLELL-PAGES LLUIS 2010-07-22 US disclosed
US-7732460-B2 Heterocyclic compounds, their preparation and their use as antibacterials GLAXO GROUP LIMITED (GB) 2010-06-08 US disclosed
EP-1963324-B1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LTD (GB) 2010-04-21 EP disclosed
US-20090036433-A1 Heterocyclic Compounds, their Preparation and their Use as Antibacterials GLAXO GROUP LIMITED (GB) 2009-02-05 US disclosed
EP-2005995-A1 Heterocyclic compounds for the treatment of tuberculosis GLAXO GROUP LIMITED (GB) 2008-12-24 EP disclosed
EP-1963324-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2008-09-03 EP disclosed
US-20070185153-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
WO-2007071936-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2007-06-28 WO disclosed
WO-1998027077-A1 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES AND THEIR USE AS ENDOTHELIN-RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185153-A1 COMPOUNDS NRDC, NISCH, MRPL21 ALDH1A1 4225/4885RAB9A 1548/4885NPC1 239/4885
US-20100184751-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS SDHA, SDHB, NNT ALDH1A1 1245/4885RAB9A 2131/4885NPC1 446/4885
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 ALDH1A1 3480/4885RAB9A 2151/4885NPC1 4313/4885
US-20090036433-A1 Heterocyclic Compounds, their Preparation and their Use as Antibacterials MRPL21, NACA, NISCH ALDH1A1 2482/4885RAB9A 1207/4885NPC1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.